PT-141 10mg (Bremelanotide) Research Peptide

PT-141 10mg, also known as Bremelanotide, is a synthetic cyclic heptapeptide research compound originally identified as a metabolite of Melanotan 2 (MT-II). PT-141 10mg is studied in laboratory and preclinical settings for its activity as an agonist of melanocortin receptors, particularly melanocortin 3 receptor and melanocortin 4 receptor. Supplied as a lyophilized powder with a reported purity greater than 99%, PT-141 10mg is intended exclusively for laboratory research use.

What Is PT-141 10mg (Bremelanotide)?

PT-141 10mg is an experimental research peptide developed to investigate melanocortin receptor–mediated signaling within the central nervous system. Unlike compounds that act directly on peripheral vascular pathways, PT-141 has been studied for its central mechanism of action, influencing neural circuits associated with arousal-related signaling, energy balance, and metabolic regulation in experimental models.

PT-141 10mg is an experimental research compound and is not approved for human or animal use.

Research Background

Melanocortin hormones and their synthetic analogs have been widely studied for their roles in regulating appetite, energy expenditure, and behavioral signaling. PT-141 emerged during research involving Melanotan peptides when investigators observed changes in arousal-related behaviors in animal models.

Subsequent research focused on PT-141’s selective engagement of melanocortin receptors, particularly MC3R and MC4R, and its ability to influence central neural pathways rather than acting through direct vascular mechanisms. All findings remain preclinical and have not been validated in human clinical trials.

Mechanisms of Research Interest

Melanocortin 3 Receptor Activation

PT-141 10mg has been studied for its potential to activate melanocortin 3 receptors, which are associated with hypothalamic signaling pathways involved in energy homeostasis, appetite regulation, and metabolic research models.

Melanocortin 4 Receptor Activation

Research suggests PT-141 may engage melanocortin 4 receptors, a receptor system studied for its involvement in arousal-related signaling, energy expenditure, and appetite-related pathways. MC4R activation has also been examined in experimental models exploring nitric oxide–related signaling.

Central Nervous System Activity

Animal studies have reported increased neuronal activity in the hypothalamus and related central nervous system regions following PT-141 exposure, supporting interest in its central signaling properties.

Nitric Oxide Pathway Research

Experimental data suggests melanocortin receptor activation by PT-141 may indirectly involve the nitric oxide–cyclic guanosine monophosphate pathway, a signaling cascade studied in relation to smooth muscle and vascular research models.

All mechanisms described are experimental observations or theoretical models and do not imply clinical or therapeutic benefit.

Molecular and Chemical Information

• Product Name: PT-141 10mg (Bremelanotide)

• Form: Lyophilized powder

• Purity: Greater than 99%

• Peptide Type: Synthetic cyclic heptapeptide

• Molecular Formula: C50H68N14O10

• Molecular Weight: 1025.18 g/mol

• Alternate Names: Bremelanotide

Research Applications

PT-141 10mg may be utilized by qualified researchers in laboratory investigations involving:

• Melanocortin receptor signaling studies

• Central nervous system pathway research

• Appetite and energy balance signaling models

• Neuroendocrine and behavioral research

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data